32161-30-1: Levodopa L-Veratrylglycine Impurity
Also known as Levodopa Dimethyl Ether, it is one of impurity present in Levodopa, Levodopa is a dopamine precursor used in the management of Parkinson’s disease, Levodopa metabolized to dopamine on side of the blood-brain barrier, so administered with a dopa decarboxylase inhibitor like carbidopa. which used to prevent metabolism until after it has crossed the blood-brain barrier. levodopa is metabolized to dopamine and used to treat symptoms of Parkinson’s.
Additional information on CAS 32161-30-1
VL420012
32161-30-1
C11H15NO4
225.24 g/mol
Levodopa
(S)-3, 4-Dimethoxyphenylalanine
Levodopa Dimethyl Ether; 3-Methoxy-O-methyl-L-tyrosine; (S)-3, 4-Dimethoxyphenylalanine; ?-(3, 4-Dimethoxyphenyl)-L-alanine; 3, 4-Dimethoxy-L-phenylalanine; DMPA; L-Veratrylglycine;
Tambasco, N., Romoli, M., & Calabresi, P. (2018). Levodopa in Parkinson’s Disease: Current Status and Future Developments. Current Neuropharmacology, 16(8), 1239–1252. https://doi.org/10.2174/1570159×15666170510143821
In-stock
